Foundation Medicine is a precision oncology company within the Roche Group that develops comprehensive genomic profiling tests. Its tests analyze more than 300 cancer-related genes to help match patients to treatment options and support cancer drug development.
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
The global precision medicine market reached $98.87 billion in 2024 and is projected to grow at 14.8% CAGR through 2033, driven by genomic sequencing advances, chronic disease prevalence, and AI-driven diagnostics adoption.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06745882 |
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC |
RECRUITING | PHASE2 |
| NCT06146920 |
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation |
ACTIVE_NOT_RECRUITING | NA |
| NCT05846594 |
A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer |
COMPLETED | NA |
| NCT05457257 |
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT05197322 |
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer |
RECRUITING | PHASE2 |
| NCT05062889 |
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients |
SUSPENDED | PHASE2 |
| NCT04849364 |
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer |
TERMINATED | PHASE2 |
| NCT04641676 |
A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center |
UNKNOWN | NA |
| NCT04504604 |
TCF-001 TRACK (Target Rare Cancer Knowledge) Study |
RECRUITING | NA |
| NCT04486352 |
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer |
RECRUITING | PHASE1/PHASE2 |
